Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 47.45
KOOL's Cash to Debt is ranked higher than
69% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. KOOL: 47.45 )
Ranked among companies with meaningful Cash to Debt only.
KOOL' s Cash to Debt Range Over the Past 10 Years
Min: 0.87  Med: 1574.98 Max: No Debt
Current: 47.45
Equity to Asset 0.67
KOOL's Equity to Asset is ranked higher than
55% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. KOOL: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
KOOL' s Equity to Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.81 Max: 0.91
Current: 0.67
0.45
0.91
Interest Coverage N/A
KOOL's Interest Coverage is ranked higher than
80% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 53.78 vs. KOOL: N/A )
Ranked among companies with meaningful Interest Coverage only.
KOOL' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 2
Z-Score: -4.19
M-Score: -2.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -94.52
KOOL's Operating margin (%) is ranked lower than
77% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. KOOL: -94.52 )
Ranked among companies with meaningful Operating margin (%) only.
KOOL' s Operating margin (%) Range Over the Past 10 Years
Min: -92.63  Med: -45.79 Max: -12.12
Current: -94.52
-92.63
-12.12
Net-margin (%) -80.85
KOOL's Net-margin (%) is ranked lower than
74% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.79 vs. KOOL: -80.85 )
Ranked among companies with meaningful Net-margin (%) only.
KOOL' s Net-margin (%) Range Over the Past 10 Years
Min: -92.58  Med: -41.14 Max: -10.97
Current: -80.85
-92.58
-10.97
ROE (%) -31.49
KOOL's ROE (%) is ranked lower than
72% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. KOOL: -31.49 )
Ranked among companies with meaningful ROE (%) only.
KOOL' s ROE (%) Range Over the Past 10 Years
Min: -35.53  Med: -26.34 Max: -13.56
Current: -31.49
-35.53
-13.56
ROA (%) -21.53
KOOL's ROA (%) is ranked lower than
68% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.56 vs. KOOL: -21.53 )
Ranked among companies with meaningful ROA (%) only.
KOOL' s ROA (%) Range Over the Past 10 Years
Min: -26.14  Med: -20.65 Max: -10.6
Current: -21.53
-26.14
-10.6
ROC (Joel Greenblatt) (%) -281.50
KOOL's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. KOOL: -281.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KOOL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -262.55  Med: -136.59 Max: -36.5
Current: -281.5
-262.55
-36.5
Revenue Growth (3Y)(%) -30.10
KOOL's Revenue Growth (3Y)(%) is ranked lower than
90% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. KOOL: -30.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KOOL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: -4.50 Max: 20.7
Current: -30.1
-30.1
20.7
EBITDA Growth (3Y)(%) 4.70
KOOL's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. KOOL: 4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KOOL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39  Med: -8.60 Max: 100.5
Current: 4.7
-39
100.5
EPS Growth (3Y)(%) 6.60
KOOL's EPS Growth (3Y)(%) is ranked higher than
58% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. KOOL: 6.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KOOL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.9  Med: -6.80 Max: 115.1
Current: 6.6
-35.9
115.1
» KOOL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-06-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

KOOL Guru Trades in

KOOL Guru Trades in

KOOL Guru Trades in

Q4 2015

KOOL Guru Trades in Q4 2015

Jim Simons 57,029 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 0.40
KOOL's Forward P/E is ranked higher than
98% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 18.69 vs. KOOL: 0.40 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.16
KOOL's P/B is ranked higher than
99% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. KOOL: 0.16 )
Ranked among companies with meaningful P/B only.
KOOL' s P/B Range Over the Past 10 Years
Min: 0.16  Med: 1.66 Max: 20.46
Current: 0.16
0.16
20.46
P/S 0.34
KOOL's P/S is ranked higher than
93% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. KOOL: 0.34 )
Ranked among companies with meaningful P/S only.
KOOL' s P/S Range Over the Past 10 Years
Min: 0.34  Med: 1.73 Max: 25.82
Current: 0.34
0.34
25.82
Current Ratio 1.45
KOOL's Current Ratio is ranked lower than
80% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. KOOL: 1.45 )
Ranked among companies with meaningful Current Ratio only.
KOOL' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 4.92 Max: 16.85
Current: 1.45
1.45
16.85
Quick Ratio 0.91
KOOL's Quick Ratio is ranked lower than
84% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. KOOL: 0.91 )
Ranked among companies with meaningful Quick Ratio only.
KOOL' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.48 Max: 15.88
Current: 0.91
0.86
15.88
Days Inventory 159.06
KOOL's Days Inventory is ranked lower than
59% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 134.42 vs. KOOL: 159.06 )
Ranked among companies with meaningful Days Inventory only.
KOOL' s Days Inventory Range Over the Past 10 Years
Min: 119.78  Med: 143.23 Max: 181.75
Current: 159.06
119.78
181.75
Days Sales Outstanding 91.30
KOOL's Days Sales Outstanding is ranked lower than
68% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 70.19 vs. KOOL: 91.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
KOOL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.82  Med: 97.88 Max: 116.79
Current: 91.3
61.82
116.79
Days Payable 154.61
KOOL's Days Payable is ranked higher than
81% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 64.85 vs. KOOL: 154.61 )
Ranked among companies with meaningful Days Payable only.
KOOL' s Days Payable Range Over the Past 10 Years
Min: 44.89  Med: 85.61 Max: 164.16
Current: 154.61
44.89
164.16

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.19
KOOL's Price/Median PS Value is ranked higher than
95% of the 248 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. KOOL: 0.19 )
Ranked among companies with meaningful Price/Median PS Value only.
KOOL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 3.97 Max: 172.52
Current: 0.19
0.31
172.52
Price/Graham Number 0.21
KOOL's Price/Graham Number is ranked higher than
97% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. KOOL: 0.21 )
Ranked among companies with meaningful Price/Graham Number only.
KOOL' s Price/Graham Number Range Over the Past 10 Years
Min: 0.33  Med: 0.57 Max: 0.81
Current: 0.21
0.33
0.81
Earnings Yield (Greenblatt) (%) -330.98
KOOL's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. KOOL: -330.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KOOL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -330.98  Med: 170.85 Max: 7391.6
Current: -330.98
-330.98
7391.6

More Statistics

Revenue(Mil) $14
EPS $ -5.57
Beta-1.60
Short Percentage of Float2.68%
52-Week Range $1.64 - 21.80
Shares Outstanding(Mil)3.00

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue(Mil) 18 134 260 803
EPS($) -5.80 6.20 16.40 49.40
EPS without NRI($) -5.80 6.20 16.40 49.40

Business Description

Industry: Medical Devices » Medical Devices
Compare:XPAR:EMG, LSE:MED, XPAR:IMPL, NAS:AMDA, XBRU:EZBG, OSTO:STIL » details
Traded in other countries:THRN.Germany,
Cesca Therapeutics Inc formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
Cesca Therapeutics T o Present A Poster At The 2016 Annual Meeting Of The European Society For Blood... Apr 07 2016
Cesca Therapeutics To Present A Poster At The 2016 Annual Meeting Of The European Society For Blood... Mar 31 2016
Cesca Therapeutics’ Indian Subsidiary Expands Cord Blood Banking Services To Additional Hospitals... Mar 30 2016
Cesca Therapeutics Appoints Vascular Surgery Expert Lars Norgren, M.D., Ph.D. to its Clinical... Mar 23 2016
Cesca Therapeutics Appoints Vascular Surgery Expert Lars Norgren, M.D., Ph.D., to its Clinical... Mar 23 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Other Events Mar 21 2016
Cesca Therapeutics to Present at the ARM 4th Annual Cell & Gene Therapy Investor Day Mar 16 2016
Big Chinese investor takes seat on struggling company's board Mar 15 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 10 2016
Cesca Therapeutics Appoints Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group, to Board of... Mar 10 2016
McClatchy plans move to boost share price and stay on NYSE Mar 08 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Mar 04 2016
Cesca Therapeutics Announces 1-for-20 Reverse Split of Common Stock Mar 04 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Mar 02 2016
Cesca Therapeutics Announces 1-for-20 Reverse Split of Common Stock Mar 02 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Mar 01 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 22 2016
CESCA THERAPEUTICS INC. Financials Feb 20 2016
Cesca Therapeutics lowers losses by cutting costs Feb 16 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Feb 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK